Picture courtesy The Indian Express
Pune: Serum Institute of India (SII) has sought emergency use authorisation (EUA) for its COVID-19 vaccine Covovax for the 12-17 age group.
Prakash Kumar Singh, Director, Government and Regulatory Affairs at SII, stated in the application that data from two studies on 2,707 children aged 12 to 17 years show that Covovax is highly efficacious, immunogenic, safe and well-tolerated in this age group, The Indian Express reported quoting official sources.
The Drugs Controller General Of India (DCGI) has already approved Covovax for emergency use among adults.
Covovax is produced in India by Pune-based Serum Institute through technology transfer from American biotechnology company Novavax.
Earlier today, DCGI granted emergency use approval to Biological E’s indigenous vaccine Corbevax for children aged 12 to 17 years.
Currently, only those in the 15-17 year age group are being inoculated in India.
Bhubaneswar: The Odisha Government has dissolved the governing bodies or managing committees of all Non-Government…
New Delhi: President Droupadi Murmu on Monday appointed former Supreme Court judge Justice V Ramasubramanian…
Bhubaneswar: Marking a significant development in eco-friendly transport in Odisha, a tripartite Memorandum of Understanding…
Mumbai: After veteran actor Mukesh Khanna, noted poet Kumar Vishwas left netizens irked with his…
Bhubaneswar: A major fire erupted at a pressure cooker company godown at Satyanagar in Bhubaneswar…
Bhubaneswar: The Bhubaneswar Municipal Corporation (BMC) on Monday announced that the Patha Utsav, which was…
This website uses cookies.